Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

557 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial.
Fasching PA, Szeto C, Denkert C, Benz S, Weber K, Spilman P, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn HP, Warm M, van Mackelenbergh M, Rabizadeh S, Schem C, Heinmöller E, Mueller V, Marmé F, Soon-Shiong P, Nekljudova V, Untch M, Loibl S. Fasching PA, et al. Among authors: loibl s. Clin Cancer Res. 2023 Jul 5;29(13):2456-2465. doi: 10.1158/1078-0432.CCR-22-2213. Clin Cancer Res. 2023. PMID: 37014668 Free PMC article.
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G. Kaufmann M, et al. Among authors: loibl s. J Clin Oncol. 2006 Apr 20;24(12):1940-9. doi: 10.1200/JCO.2005.02.6187. J Clin Oncol. 2006. PMID: 16622270
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S. Kaufmann M, et al. Among authors: loibl s. Ann Oncol. 2007 Dec;18(12):1927-34. doi: 10.1093/annonc/mdm201. Epub 2007 Nov 12. Ann Oncol. 2007. PMID: 17998286 Free article. Review.
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group. von Minckwitz G, et al. Among authors: loibl s. Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1. Breast Cancer Res. 2008. PMID: 18380893 Free PMC article. Clinical Trial.
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M; German Breast Group. von Minckwitz G, et al. Among authors: loibl s. J Natl Cancer Inst. 2008 Apr 16;100(8):552-62. doi: 10.1093/jnci/djn089. Epub 2008 Apr 8. J Natl Cancer Inst. 2008. PMID: 18398094 Clinical Trial.
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M; German Breast Group. von Minckwitz G, et al. Among authors: loibl s. J Natl Cancer Inst. 2008 Apr 16;100(8):542-51. doi: 10.1093/jnci/djn085. Epub 2008 Apr 8. J Natl Cancer Inst. 2008. PMID: 18398097 Clinical Trial.
NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas.
Engels K, Knauer SK, Loibl S, Fetz V, Harter P, Schweitzer A, Fisseler-Eckhoff A, Kommoss F, Hanker L, Nekljudova V, Hermanns I, Kleinert H, Mann W, du Bois A, Stauber RH. Engels K, et al. Among authors: loibl s. Cancer Res. 2008 Jul 1;68(13):5159-66. doi: 10.1158/0008-5472.CAN-08-0406. Cancer Res. 2008. PMID: 18593915
557 results